GeoVax Labs is a clinical-stage biotechnology company that develops vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms based on Modified Vaccinia Ankara (MVA) and adenovirus vectors. The company's lead programs include GEO-MVA, an MVA-based vaccine for poxviruses including mpox and smallpox suitable for high-risk populations; Gedeptin, a gene-directed enzyme prodrug therapy for solid tumors being evaluated in combination with immune checkpoint inhibitors; and GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine showing enhanced immune responses. GeoVax generates value by advancing product candidates through clinical development and pursuing regulatory approval and commercialization via internal development and selective partnerships with academic, governmental, and industry partners, while relying on third-party contract manufacturing organizations and licensing intellectual property from university and governmental sources.